JULIE HAUSNER: Open Payments
NPI 1952655482 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$579 in 26 payments from 12 companies in 2025. Trend: 2023 $520 · 2024 $574 · 2025 $579
Food & beverage: $579
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 5 | $113 |
| Mallinckrodt Hospital Products Inc. | 5 | $113 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $80 |
| Madrigal Pharmaceuticals | 3 | $75 |
| Azurity Pharmaceuticals, Inc. | 2 | $57 |
| Ethicon US, LLC | 1 | $43 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $18 |
| TriSalus Life Sciences, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
Products named: TERLIVAZ, XIFAXAN, REZDIFFRA, VISTASEAL, OCALIVA, Rezzayo, TRINAV INFUSION SYSTEM, IQIRVO.
Industry payments across GA — which companies pay providers there.
